GlassScriptPhysician profile
Reagan E Elkins
NPI 1366444994
$9,123.33
in general payments reported to CMS, 2019-2025
49 companies · $365 in 2025
The $365 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,412 · 2020: $1,585 · 2021: $2,121 · 2022: $1,678 · 2023: $1,514 · 2024: $449 · 2025: $365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,327.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,264.32 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,046.87 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $562.95 | 2021-2025 | |
| Lilly USA, LLC | $453.94 | 2019-2025 | Jardiance, Mounjaro, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $395.16 | 2019-2024 | Jardiance |
| Abbott Laboratories | $392.99 | 2021-2025 | Freestyle Libre 3, Freestyle Libre |
| Sanofi-Aventis U.S. LLC | $372.74 | 2019-2022 | |
| Pfizer INC. | $366.11 | 2019-2025 | |
| Astellas Pharma US INC | $360.78 | 2021-2024 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $336.05 | 2019-2023 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $310.09 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $297.20 | 2019-2022 | |
| Allergan, INC. | $287.48 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $276.02 | 2019-2024 | Gardasil, Gardasil 9 |
| Bayer Healthcare Pharmaceuticals INC. | $269.70 | 2022-2025 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reagan Elkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.